Document Detail

Disproportional response between refractory period and blood flow to alpha 1- and beta-adrenoceptor blockade in canine ischemic myocardium.
MedLine Citation:
PMID:  10410826     Owner:  NLM     Status:  MEDLINE    
We investigated the response of refractory periods and blood flow to blockade of alpha 1- and beta-adrenoceptors alone, or in combination on endocardium and epicardium, during myocardial ischemia. Dogs were anesthetized with alpha-chloralose and divided into bunazosin (an alpha 1-blocking agent)-treated (0.1-0.2 mg/kg, i.v., n = 14), propranolol-treated (0.2 mg/kg, i.v., n = 12), and vehicle-control (n = 10) groups. The diagonal branches of the left anterior descending artery were ligated. The refractory period (ERP) and blood flow (RMBF) were determined by an S1-S2 extrastimulus method and a nonradioactive microsphere technique, respectively. The duration of regional electrograms (DRE) was measured in the endocardial and epicardial sites. Bunazosin alone reversed the ischemia-related shortening of ERPs at both the endocardial and epicardial sites, with a greater effect seen epicardially (P < .05). Subsequent administration of propranolol further prolonged ERPs in both sites, although the effect was greater in the epicardial surface (P < .05). Bunazosin reduced RMBF to a greater degree at the endocardial site than at the epicardial site in the ischemic zone (P < .01 and P < .05, respectively), but the magnitude of the reduction in RMBF and the difference in RMBF between sites were similar to the control group (P < .01). Propranolol alone and subsequent administration of bunazosin prolonged the ERP more at the epicardial site (P < .01) than at the endocardial sites in the ischemic zone. Propranolol produced no significant difference in RMBF between both sites. DREs in animals treated with bunazosin and propranolol alone, or in combination, were similar to those in animals treated with vehicle. These results suggest that differences in ERPs between endocardium and epicardium with blockade of alpha 1- and/or beta-adrenoceptor are not due to concomitant alterations in RMBF, but to differences in electrophysiological properties of the endocardial and epicardial cells during the acute phase of myocardial ischemia.
K Usui; T Tanabe; S Handa; Y Shinozaki; H Mori
Related Documents :
2641906 - Metabolic consequences of coronary stenosis. transmurally heterogeneous myocardial isch...
11395046 - Reduced myocardial flow reserve relates to increased carotid intima-media thickness in ...
3344826 - Aortic pressure reduction redistributes transmural blood flow in dog left ventricle.
6720916 - Transmural changes in porcine and canine hearts after circumflex artery occlusion.
10793596 - Effects of the sitting position on the distribution of blood volume in patients undergo...
12100416 - Reference values for ductus venosus doppler flow measurements at 10-14 weeks of gestation.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  12     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-09-14     Completed Date:  1999-09-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  561-71     Citation Subset:  IM    
Department of Cardiovascular Medicine, Tokai University, Kanagawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic alpha-Antagonists / pharmacology*
Adrenergic beta-Antagonists / pharmacology*
Blood Pressure / drug effects
Coronary Circulation / drug effects*
Electrocardiography / drug effects
Endocardium / drug effects
Heart / drug effects
Myocardial Ischemia / physiopathology*
Pericardium / drug effects
Propranolol / pharmacology
Quinazolines / pharmacology
Receptors, Adrenergic, alpha-1 / antagonists & inhibitors*
Refractory Period, Electrophysiological / drug effects*
Tachycardia, Ventricular / physiopathology
Ventricular Fibrillation / physiopathology
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Adrenergic beta-Antagonists; 0/Quinazolines; 0/Receptors, Adrenergic, alpha-1; 525-66-6/Propranolol; 80755-51-7/bunazosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beta-adrenergic blockade decreases coronary collateral blood flow in patients with coronary artery d...
Next Document:  Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide o...